Docosahexaenoic Acid-Rich Fish Oil Supplementation Reduces Kinase Associated with Insulin Resistance in Overweight and Obese Midlife Adults.
Rohith N ThotaJessica I RosatoTracy L BurrowsCintia B DiasKylie A AbbottRalph N MartinsManohar L GargPublished in: Nutrients (2020)
Targeting kinases linked to insulin resistance (IR) and inflammation may help in reducing the risk of type 2 diabetes (T2D) and Alzheimer's disease (AD) in its early stages. This study aimed to determine whether DHA-rich fish oil supplementation reduces glycogen synthase kinase (GSK-3), which is linked to both IR and AD. Baseline and post-intervention plasma samples from 58 adults with abdominal obesity (Age: 51.7 ± 1.7 years, BMI: 31.9 ± 0.8 kg/m2) were analysed for outcome measures. Participants were allocated to 2 g DHA-rich fish oil capsules (860 mg DHA + 120 mg EPA) (n = 31) or placebo capsules (n = 27) per day for 12 weeks. Compared to placebo, DHA-rich fish oil significantly reduced GSK-3β by -2.3 ± 0.3 ng/mL. An inverse correlation (p < 0.05) was found between baseline insulin and IR and their changes following intervention only in participants with C-reactive protein levels higher than 2.4 mg/L. DHA-rich fish oil reduces GSK-3 and IR, suggesting a potential role of long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) in ameliorating AD risk.
Keyphrases
- fatty acid
- type diabetes
- insulin resistance
- randomized controlled trial
- metabolic syndrome
- signaling pathway
- pi k akt
- glycemic control
- cardiovascular disease
- tyrosine kinase
- skeletal muscle
- high fat diet induced
- protein kinase
- polycystic ovary syndrome
- cell proliferation
- clinical trial
- climate change
- cancer therapy
- preterm birth
- study protocol